Kestra Medical Technologies, Ltd. $KMTS Shares Sold by Omega Fund Management LLC

Omega Fund Management LLC trimmed its holdings in Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 16.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,373,591 shares of the company’s stock after selling 272,302 shares during the quarter. Kestra Medical Technologies comprises about 12.7% of Omega Fund Management LLC’s holdings, making the stock its 5th biggest holding. Omega Fund Management LLC’s holdings in Kestra Medical Technologies were worth $36,428,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Farther Finance Advisors LLC acquired a new position in Kestra Medical Technologies during the 4th quarter worth about $31,000. China Universal Asset Management Co. Ltd. acquired a new position in Kestra Medical Technologies during the 3rd quarter worth about $48,000. BNP Paribas Financial Markets lifted its position in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after buying an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in Kestra Medical Technologies during the 4th quarter worth about $72,000. Finally, Brown Brothers Harriman & Co. lifted its position in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares in the last quarter.

Wall Street Analyst Weigh In

KMTS has been the topic of several research reports. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. BTIG Research reiterated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Finally, The Goldman Sachs Group reduced their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $27.40.

Insider Transactions at Kestra Medical Technologies

In related news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the transaction, the insider owned 334,786 shares in the company, valued at $7,017,114.56. This trade represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.60% of the stock is currently owned by corporate insiders.

Kestra Medical Technologies Price Performance

Kestra Medical Technologies stock opened at $19.23 on Wednesday. The business’s 50-day simple moving average is $20.70 and its 200 day simple moving average is $22.97. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -4.86 and a beta of 0.83. Kestra Medical Technologies, Ltd. has a 12-month low of $13.25 and a 12-month high of $30.00. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The company’s revenue was up 62.7% on a year-over-year basis. As a group, research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.34 earnings per share for the current year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.